Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D., Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis, «CURRENT ONCOLOGY», 2022, 29, pp. 5846 - 5854 [articolo]Open Access
Ambrosini, Valentina; Zanoni, Lucia; Filice, Angelina; Lamberti, Giuseppe; Argalia, Giulia; Fortunati, Emilia; Campana, Davide; Versari, Annibale; Fanti, Stefano, Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors, «CANCERS», 2022, 14, pp. 1055 - 1083 [articolo]Open Access
Magi L.; Prosperi D.; Lamberti G.; Marasco M.; Ambrosini V.; Rinzivillo M.; Campana D.; Gentiloni G.; Annibale B.; Signore A.; Panzuto F., Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors, «ENDOCRINE», 2022, 76, pp. 1392 - 1399 [articolo]Open Access
Panzuto F.; Ricci C.; Rinzivillo M.; Magi L.; Marasco M.; Lamberti G.; Casadei R.; Campana D., The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 6127, pp. 1 - 11 [articolo]Open Access
Tabacchi E.; Fortunati E.; Argalia G.; Zanoni L.; Calabro D.; Telo S.; Campana D.; Lamberti G.; Ricci C.; Casadei R.; Fanti S.; Ambrosini V., [68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?, «CANCERS», 2022, 14, Article number: 3541, pp. 1 - 10 [articolo]Open Access
Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G., An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances, «PHARMACEUTICALS», 2021, 14, Article number: 316, pp. 316 - 339 [articolo]Open Access
Cortellini A.; Ricciuti B.; Facchinetti F.; Alessi J.V.M.; Venkatraman D.; Dall'Olio F.G.; Cravero P.; Vaz V.R.; Ottaviani D.; Majem M.; Piedra A.; Sullivan I.; Lee K.A.; Lamberti G.; Hussain N.; Clark J.; Bolina A.; Barba A.; Benitez J.C.; Gorria T.; Mezquita L.; Hoton D.; Aboubakar Nana F.; Besse B.; Awad M.M.; Pinato D.J., Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy, «ANNALS OF ONCOLOGY», 2021, 32, pp. 1391 - 1399 [articolo]
Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M., Antibody–drug conjugates for lung cancer in the era of personalized oncology, «SEMINARS IN CANCER BIOLOGY», 2021, 69, pp. 268 - 278 [articolo]
Nebhan C.A.; Cortellini A.; Ma W.; Ganta T.; Song H.; Ye F.; Irlmeier R.; Debnath N.; Saeed A.; Radford M.; Alahmadi A.; Diamond A.; Hoimes C.; Ramaiya N.; Presley C.J.; Owen D.H.; Abou Alaiwi S.; Nassar A.; Ricciuti B.; Lamberti G.; Bersanelli M.; Casartelli C.; Buti S.; Marchetti P.; Giusti R.; Filetti M.; Vanella V.; Mallardo D.; Macherla S.; Sussman T.A.; Botticelli A.; Galetta D.; Catino A.; Pizzutilo P.; Genova C.; Dal Bello M.G.; Kalofonou F.; Daniels E.; Ascierto P.A.; Pinato D.J.; Choueiri T.K.; Johnson D.B.; Marron T.U.; Wang Y.; Naqash A.R., Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study, «JAMA ONCOLOGY», 2021, 7, pp. 1856 - 1861 [articolo]
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3), «BRITISH JOURNAL OF CANCER», 2021, 125, pp. 306 - 306 [replica/breve intervento]
Ricco G.; Andrini E.; Siepe G.; Mosconi C.; Ambrosini V.; Ricci C.; Casadei R.; Campana D.; Lamberti G., Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading?, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 10629, pp. 10629 - 10643 [articolo]Open Access
Telo S.; Filice A.; Versari A.; Lamberti G.; Campana D.; Calabro D.; Fanti S.; Ambrosini V., Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications, «CLINICAL AND TRANSLATIONAL IMAGING», 2021, 9, pp. 423 - 438 [articolo]
Ingaldi C.; Alberici L.; Ricci C.; Campana D.; Mosconi C.; Ambrosini V.; Lamberti G.; Manuzzi L.; Minni F.; Casadei R., Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis, «UPDATES IN SURGERY», 2021, 74, pp. 991 - 998 [articolo]Open Access
Rossi R.E.; Milanetto A.C.; Andreasi V.; Campana D.; Coppa J.; Nappo G.; Rinzivillo M.; Invernizzi P.; Modica R.; David A.; Partelli S.; Lamberti G.; Mazzaferro V.; Zerbi A.; Panzuto F.; Pasquali C.; Falconi M.; Massironi S., Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy, «JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION», 2021, 44, pp. 2227 - 2234 [articolo]
Massironi S.; Campana D.; Pusceddu S.; Albertelli M.; Faggiano A.; Panzuto F.; Smiroldo V.; Andreasi V.; Rossi R.E.; Maggio I.; Torchio M.; Dotto A.; Modica R.; Rinzivillo M.; Carnaghi C.; Partelli S.; Fanetti I.; Lamberti G.; Corti F.; Ferone D.; Colao A.; Annibale B.; Invernizzi P.; Falconi M., Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study, «DIGESTIVE AND LIVER DISEASE», 2021, 53, pp. 367 - 374 [articolo]
